Chugai Pharma Science (Beijing) Co., Ltd.

A double-blind, controlled (once a week for 5 weeks) clinical trial in patients with knee osteoarthritis, using Aldridge as a control, to evaluate the safety and efficacy of NRD101

Using Alzhi as a positive control drug, the safety and efficacy of NRD101 were studied in patients with periarthritis of the shoulder in a double-blind, controlled manner (administered once a week for 5 consecutive weeks).

Methods: The pharmacokinetics of a single oral dose of ED-71 (0.5 μg and 0.75 μg) on an empty stomach was studied in healthy adult males using a 2×2 crossover design (unblinded), and its safety was also evaluated.